REPLIMUNE GROUP INC's ticker is REPL and the CUSIP is 76029N106. A total of 107 filers reported holding REPLIMUNE GROUP INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $614,163 | -39.9% | 35,895 | -18.4% | 0.00% | 0.0% |
| Q2 2023 | $1,021,704 | +76.8% | 44,001 | +34.5% | 0.00% | 0.0% |
| Q1 2023 | $577,853 | -20.8% | 32,721 | +21.9% | 0.00% | 0.0% |
| Q4 2022 | $729,830 | +119.2% | 26,832 | +39.5% | 0.00% | – |
| Q3 2022 | $333,000 | +13.3% | 19,237 | +14.0% | 0.00% | – |
| Q2 2022 | $294,000 | +5.8% | 16,873 | +3.0% | 0.00% | – |
| Q1 2022 | $278,000 | -35.8% | 16,382 | +2.5% | 0.00% | – |
| Q4 2021 | $433,000 | -2.7% | 15,983 | +6.6% | 0.00% | – |
| Q3 2021 | $445,000 | -18.6% | 14,994 | +5.2% | 0.00% | – |
| Q2 2021 | $547,000 | -7.3% | 14,250 | -26.4% | 0.00% | – |
| Q1 2021 | $590,000 | -69.1% | 19,354 | -61.3% | 0.00% | -100.0% |
| Q4 2020 | $1,907,000 | +688.0% | 49,999 | +375.1% | 0.00% | – |
| Q3 2020 | $242,000 | -50.3% | 10,524 | -78.5% | 0.00% | – |
| Q1 2020 | $487,000 | – | 48,924 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 3,050,187 | $53,866,302 | 35.13% |
| Atlas Venture Life Science Advisors, LLC | 2,098,300 | $37,055,978 | 5.02% |
| Redmile Group, LLC | 3,811,988 | $67,319,708 | 2.92% |
| Nan Fung Group Holdings Ltd | 189,339 | $3,343,727 | 2.28% |
| Altium Capital Management LP | 148,000 | $2,613,680 | 1.45% |
| Integral Health Asset Management, LLC | 395,000 | $6,975,700 | 1.40% |
| BVF INC/IL | 2,143,036 | $37,846,016 | 1.38% |
| Resolute Capital Asset Partners LLC | 82,500 | $1,457 | 1.06% |
| SECTORAL ASSET MANAGEMENT INC | 262,200 | $4,630,452 | 0.89% |
| Frazier Life Sciences Management, L.P. | 686,762 | $12,128,217 | 0.88% |